Biopharma capital surge builds case for lab leasing rebound

Massachusetts biopharma employment fell in 2025 for the first time in the two decades MassBio has tracked the sector, slipping 3.1% to 113,503 jobs. The state's drug developers raised $3.45 billion in venture capital in the first half of 2026, up 25% year over year and the strongest opening six months since 2023. The gap between those two lines is the case for a 2027 lab leasing recovery.

Lab leasing in Cambridge and along Route 128 tracks headcount, and a payroll contraction of that size produces vacancy, concessions, and slower lease-up times across life-science assets. For owners underwriting lab buildings, the jobs line is the rearview mirror — it records what the 2025 rent roll already absorbed, not where the next funding cycle is pointing.

MassBio's 2026 Industry Snapshot, as reported by Connect CRE, shows the capital side pointing the other way. The $3.45 billion in venture funding that Massachusetts companies raised in the first half of 2026 amounted to a quarter of all US biopharma VC, behind California's 43.4% share and ahead of every other state, none of which reached 6%. Eight Massachusetts companies went public in the first six months, matching the combined IPO total of 2024 and 2025 and accounting for nearly two-thirds of US biotech listings. M&A returned as well: 11 companies were acquired for a reported $18.0 billion, against $7.6 billion disclosed a year earlier.

Venture dollars and listings do not lease space on the day they close. A company raising a late-stage round is usually six months to two years from signing a lab lease, and a newly public biotech needs to hire scientists before showing revenue growth, which means benches and lab space before profits. That lag is why the jobs decline and the capital resurgence can be true at the same time — the first is the 2025 rent roll, the second is the 2027 leasing pipeline.

For a landlord who marked assets to the jobs line at the end of last year, the funding line has already turned. Headcount repriced the market in 2025; capital is repricing it back in 2026, and the gap between the two is what makes the moment investable.

The trade for landlords is to hold rather than dump. The same patient-capital discipline showing up across office and multifamily — owners preferring structured extensions and preferred equity over fire sales — has an application in lab space: vacancy carried through the trough becomes capture when funding turns into headcount. That trade carries timing risk, because IPOs slip and acquisitions often consolidate payrolls rather than grow them. But the direction of the capital is clear, and in leasing, direction matters more than the quarter.